- Business
- Daihan Pharmaceutical Co., Ltd. (023910.KS) manufactures and markets pharmaceutical products in South Korea, with a primary focus on infusion solutions, injectables, and related therapeutics; the company produces over 200 types of finished medicines including basic infusions, special infusions, nutritional infusions, parenteral sterilized products such as ampules and vials, large-volume infusions, dialysis solutions, antibiotics, anesthetics, antispasmodics, respiratory drugs, vitamin-mineral supplements, antidotes, hormones, hepatic protectors, hypnotics-sedatives, analgesics, irrigations, ointments, inhalants, over-the-counter (OTC) drugs like sterile sodium chloride irrigation and water for irrigation, and quasi-drugs such as Eye-con contact lens cleaning solution. Daihan supplies its prescription, OTC, and quasi-drugs to hospitals, private pharmacies, and other healthcare providers through its own sales network, while also engaging in exports of infusion and injection solutions, technology transfers for plant-related knowhow, and research and development activities. Founded in 1945 and headquartered in Seoul with manufacturing facilities in Ansan-si, Gyeonggi-do, the company operates primarily in the domestic Korean market but pursues export expansion and diversification. In recent years, Daihan completed a significant plant expansion and reconstruction in 2013 and reserved additional land in 2018 for a new facility with 16,567.3 square meters of gross land area and 31,463.184 square meters of building area to support long-term growth and high-tech infusion production. The company maintains around 553 employees and continues to emphasize quality assurance, environmental management, and innovation in its sterile liquid drug production capabilities.